JP2020533362A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533362A5
JP2020533362A5 JP2020514968A JP2020514968A JP2020533362A5 JP 2020533362 A5 JP2020533362 A5 JP 2020533362A5 JP 2020514968 A JP2020514968 A JP 2020514968A JP 2020514968 A JP2020514968 A JP 2020514968A JP 2020533362 A5 JP2020533362 A5 JP 2020533362A5
Authority
JP
Japan
Prior art keywords
sequence
seq
variable region
multispecific antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020514968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/050931 external-priority patent/WO2019055689A1/en
Publication of JP2020533362A publication Critical patent/JP2020533362A/ja
Publication of JP2020533362A5 publication Critical patent/JP2020533362A5/ja
Pending legal-status Critical Current

Links

Images

JP2020514968A 2017-09-13 2018-09-13 エクト酵素に結合する重鎖抗体 Pending JP2020533362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558147P 2017-09-13 2017-09-13
US62/558,147 2017-09-13
PCT/US2018/050931 WO2019055689A1 (en) 2017-09-13 2018-09-13 HEAVY CHAIN ANTIBODIES BINDING TO EXOENZYMES

Publications (2)

Publication Number Publication Date
JP2020533362A JP2020533362A (ja) 2020-11-19
JP2020533362A5 true JP2020533362A5 (https=) 2021-11-04

Family

ID=63714117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514968A Pending JP2020533362A (ja) 2017-09-13 2018-09-13 エクト酵素に結合する重鎖抗体

Country Status (13)

Country Link
US (1) US20200207867A1 (https=)
EP (1) EP3681908A1 (https=)
JP (1) JP2020533362A (https=)
KR (1) KR20200044094A (https=)
CN (1) CN111133007A (https=)
AU (1) AU2018331421A1 (https=)
BR (1) BR112020004846A2 (https=)
CA (1) CA3075399A1 (https=)
IL (1) IL273235A (https=)
MX (1) MX2020002802A (https=)
RU (1) RU2020112490A (https=)
SG (1) SG11202002093TA (https=)
WO (1) WO2019055689A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264941B2 (en) 2016-08-24 2025-12-01 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
JP7776987B2 (ja) 2019-04-05 2025-11-27 テネオバイオ， インコーポレイテッド Ｐｓｍａに結合する重鎖抗体
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
WO2021127489A1 (en) * 2019-12-18 2021-06-24 Teneobio, Inc. Heavy chain antibodies binding to cd38
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
MX2008012843A (es) 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TW201129384A (en) * 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG10201803288RA (en) * 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
CN110627907B (zh) * 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
JP6775422B2 (ja) * 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
CN107207594B (zh) * 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
MX389805B (es) * 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
MA43219A (fr) * 2015-11-10 2018-09-19 Univ Medical Center Hamburg Eppendorf Polypeptides de liaison d'antigène dirigés contre cd38

Similar Documents

Publication Publication Date Title
JP2020533362A5 (https=)
JP2020519600A5 (https=)
JP2021527431A5 (https=)
JP2019110906A5 (https=)
JP2014158469A5 (https=)
JP2021511811A5 (https=)
JP2018519263A5 (https=)
JP2021525248A5 (https=)
JP2017528462A5 (https=)
JP2011046732A5 (https=)
JP2015508280A5 (https=)
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
JP2017501157A5 (https=)
JP2018506277A5 (https=)
JP2015532292A5 (https=)
JP2014530215A5 (https=)
IL265541B2 (en) Bispecific antibodies and compounds containing them for the treatment of cancer
JP2018513149A5 (https=)
JP2018500014A5 (https=)
JP2018507220A5 (https=)
JP2021510736A5 (https=)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2015520758A5 (https=)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
RU2019140356A (ru) Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений